A clinical ly relevant but not statistically significant reduction in triglycerides was found .
No impact on HDL-C levels was found .
Patients ' adherence to pharmacotherapeutic regimens and quality of life were considered possibly not sensitive and possibly sensitive to pharmacist interventions , respectively .
Total cholesterol is sensitive to pharmacist interventions , while LDL-C and triglyceride levels are possibly sensitive to those interventions .
BACKGROUND Hyperlipidemia increases the risk of cardiovascular diseases , and control is pivotal for preventing disease complications .
Multidisciplinary interventions , including those performed by pharmacists , are important for improving patients ' outcomes .
OBJECTIVE To quantify the impact of pharmacist interventions in enhancing patients ' outcomes .
Effect of pharmaceutical care on optimum colestipol treatment in elderly hypercholesterolemic veterans.
We conducted a prospect i ve trial to determine whether a formal , integrated pharmaceutical care plan can enhance patient acceptance and compliance with colestipol therapy and improve outcomes .  Forty patients with hypercholesterolemia were equally divided and assigned to either a usual care or pharmaceutical care group . In the pharmaceutical care group compared with the usual care group , after 52 weeks , colestipol therapy result ed in a greater reduction in total cholesterol ( 12.5 % vs 7.3 % ) , low-density lipoprotein cholesterol ( LDL-C ; 16 % vs 9.4 % ) , and LDL-C : high-density lipoprotein cholesterol ( HDL-C ) ratio ( 24.4 % vs 12.2 % , p < 0.05 ) . The percentage of patients who achieved their LDL-C goal at week 52 was much greater in the pharmaceutical care group ( 29.4 % ) than in the usual care group ( 5.0 % , p < 0.05 ) . Co-management by a physician and a pharmacist of hypercholesterolemic veterans treated with colestipol can enhance patient acceptance of the drug , LDL-C reduction , and achievement of therapeutic goals
A clinical ly relevant but not statistically significant reduction in triglycerides was found .
No impact on HDL-C levels was found .
Patients ' adherence to pharmacotherapeutic regimens and quality of life were considered possibly not sensitive and possibly sensitive to pharmacist interventions , respectively .
Total cholesterol is sensitive to pharmacist interventions , while LDL-C and triglyceride levels are possibly sensitive to those interventions .
BACKGROUND Hyperlipidemia increases the risk of cardiovascular diseases , and control is pivotal for preventing disease complications .
Multidisciplinary interventions , including those performed by pharmacists , are important for improving patients ' outcomes .
OBJECTIVE To quantify the impact of pharmacist interventions in enhancing patients ' outcomes .